Correlation of response to treatment and HIV genotypic changes during Phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy

Abstract

Virological failure during combination therapy can be due to resistance to either treatment drug, emphasising the need to change both the reverse transcriptase inhibitor and the protease inhibitor. Only Val48 and Met90 correlated directly with the development of reduced drug sensitivity during treatment with SQV in vivo.